Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | FADS1 | O60427 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 4/20 | 0.60 |
| ▸ | BRAF | P15056 | 4/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.54 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568397 | 0.86 | EGFR (0.68) | EGFRFADS1LCKNPC1POLB | |
| SCHEMBL5569110 | 0.83 | EGFR (0.60) | EGFRFADS1LCKNPC1MEN1 | |
| SCHEMBL5569001 | 0.83 | EGFR (0.60) | EGFRNPC1MEN1KMT2APOLB | |
| SCHEMBL29236749 | 0.82 | ABCG2 (0.62) | EGFRFADS1RAF1BRAFNPC1 | |
| SCHEMBL5568040 | 0.81 | EGFR (0.60) | EGFRFADS1LCKNPC1MEN1 | |
| SCHEMBL9017045 | 0.79 | TTBK1 (0.61) | EGFRFADS1LCKNPC1MEN1 | |
| SCHEMBL11091920 | 0.77 | TTBK1 (0.59) | EGFRFADS1LCKNPC1MEN1 | |
| SCHEMBL11092575 | 0.77 | EGFR (0.63) | EGFRFADS1LCKNPC1MEN1 | |
| SCHEMBL14027230 | 0.76 | EGFR (0.75) | EGFRFADS1LCKNPC1MEN1 | |
| Hydrochloric Acid SCHEMBL11088198 | 0.76 | EGFR (0.62) | EGFRFADS1LCKNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885FADS1 4484/4885RAF1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.